According the Bloomberg News, Bristol-Myers Squibb
Assuming Bloomberg's sources are telling the truth, it's likely they were ordered by their bosses to leak the info; these things are rarely just a couple of people bragging to a reporter. The question is, which side of the aisle did the leaks come from? Did Amylin put it out there looking for a higher bid, or is Bristol-Myers trying to gain some leverage through the leak?
With shares trading substantially above the rumored offer price, investors are clearly expecting something better to come along, but I wouldn't hold my breath waiting for a substantially higher bid from Bristol-Myers. The pharma has shown willingness to make purchases, but not at exuberant prices. For example, Bristol-Myers made an unsolicited offer to buy ImClone Systems a few years ago for a low-balled $60 per share. The pharma did eventually up its offer, but only by a measly 3.3% to $62. Eli Lilly
Eli Lilly isn't going to come to Amylin's rescue like it did for ImClone. The two were partners on Byetta and Bydureon before Eli Lilly found a new beau and asked for a divorce. Diabetes specialist Novo Nordisk
That leaves Merck, which sells blockbuster Januvia, and Sanofi
Given the lack of information about what potential bidders are thinking, it seems pretty risky to buy Amylin at this level. And there's always the possibility that Bristol-Myers leaked the rumor hoping to make it more difficult for Amylin to find a partner outside the U.S. to take over Eli Lilly's duties, which are set to transition to Amylin by the end of 2013. Not being able to find a partner would make Amylin less valuable, not more valuable, since it's more cost-effective to have someone else market the drugs overseas.
Fool analysts think these three American companies are set to dominate the world.
Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.